STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co., Inc. - MRK STOCK NEWS

Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.

Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.

Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.

Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.

The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.

From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.

News

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Rhea-AI Summary
Daiichi Sankyo and Merck announce the dosing of the first patient in the REJOICE-Ovarian01 trial for investigational drug R-DXd in platinum-resistant ovarian cancer. The trial aims to evaluate the drug's efficacy compared to chemotherapy in patients with advanced ovarian cancer, addressing the critical need for innovative therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.35%
Tags
clinical trial
-
News

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

Rhea-AI Summary
Merck (MRK) to host first-quarter 2024 sales and earnings conference call on April 25, providing an overview of the company's performance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
earnings
-
News

How We Can Strengthen Vaccination Programs and Build Vaccine Confidence Together

Rhea-AI Summary
Merck leaders discuss efforts to address vaccine-preventable illnesses and combat vaccine hesitancy, emphasizing collaboration and equity to improve global vaccination programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
News

European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults

Rhea-AI Summary
Merck's KEYTRUDA receives EC approval for neoadjuvant and adjuvant treatment in resectable NSCLC in Europe, marking the first anti-PD-1/L1 therapy approved for this indication. The approval is based on positive overall survival results from the Phase 3 KEYNOTE-671 trial, showing significant improvements in OS and EFS. This milestone expands KEYTRUDA's indications to six in NSCLC and 27 overall in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
-
News

FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)

Rhea-AI Summary
Merck (MRK) receives FDA approval for WINREVAIR, a breakthrough therapy for pulmonary arterial hypertension (PAH), showing significant clinical benefits in improving exercise capacity and reducing clinical worsening events. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, offering a new treatment pathway.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
fda approval
-
News

Merck Foundation Strengthens Its Commitment to Expanding Access to Care in Asia-Pacific Region

Rhea-AI Summary
The Merck Foundation, funded by Merck (NYSE:MRK), commits $11 million over six years to support healthcare in underserved communities, training 33,000 local health workers in India, Indonesia, Malaysia, and Vietnam. This builds on a previous $7 million commitment to improve access to specialty care for chronic conditions in India and Vietnam.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
none
News

Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer

Rhea-AI Summary
Merck's Phase 3 KEYLYNK-006 trial evaluating KEYTRUDA in combination with LYNPARZA did not meet primary endpoints for certain patients with metastatic nonsquamous NSCLC. Safety profiles were consistent, and further data evaluation is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
clinical trial
-
News

Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Rhea-AI Summary
Merck (MRK) announces positive data from Phase 3 trials of V116, a potential pneumococcal conjugate vaccine for adults, at the 13th ISPPD meeting. V116 shows immunogenicity across various adult populations and higher immune responses for unique serotypes. FDA granted V116 priority review with a PDUFA date of June 17, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
News

FarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

Rhea-AI Summary
FarmSee partners with MSD Animal Health to integrate AI-based weighing technology for swine monitoring. The collaboration aims to optimize swine production globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
none
News

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival (OS) Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Rhea-AI Summary
Merck's Phase 3 KEYNOTE-A18 trial with KEYTRUDA plus CRT shows significant improvement in OS for patients with high-risk locally advanced cervical cancer. The combination therapy met its primary endpoint of overall survival, demonstrating a statistically significant and clinically meaningful benefit compared to CRT alone. The safety profile was consistent with previous studies, with no new safety signals identified. These results support the FDA's approval of KEYTRUDA in combination with CRT for the treatment of patients with FIGO Stage III-IVA cervical cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
none

FAQ

What is the current stock price of Merck & Co. (MRK)?

The current stock price of Merck & Co. (MRK) is $101.16 as of November 25, 2024.

What is the market cap of Merck & Co. (MRK)?

The market cap of Merck & Co. (MRK) is approximately 256.1B.

What are the main therapeutic areas Merck focuses on?

Merck focuses on several therapeutic areas including cardiometabolic diseases, cancer, and infections. They also have a significant vaccine business and an animal health division.

What is Merck for Mothers?

Merck for Mothers is Merck’s global initiative dedicated to improving maternal health. The program has reached over 30 million women with initiatives that promote safe, high-quality care during pregnancy and childbirth.

What are some of Merck’s key products in oncology?

Merck's oncology portfolio includes KEYTRUDA, an immunotherapy used to treat various cancers, including melanoma. KEYTRUDA has shown significant benefits when used in combination with other therapies.

How significant is Merck’s vaccine business?

Merck has a substantial vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their vaccines portfolio is a major contributor to their public health impact.

Where is Merck headquartered?

Merck is headquartered in Rahway, New Jersey, USA.

What percentage of Merck’s sales comes from the United States?

Approximately half of Merck's sales are generated in the United States.

What is Merck's approach to research and development?

Merck invests heavily in research and development with over 2,250 ongoing clinical trials. Their approach focuses on innovative treatments and combination regimens to address complex health challenges.

What recent achievements has Merck announced?

Merck recently surpassed its goal of reaching 25 million women with its maternal health initiative, Merck for Mothers, by reaching over 30 million women. Additionally, they have reported promising results from clinical trials involving KEYTRUDA.

Does Merck collaborate with other companies for research?

Yes, Merck is actively involved in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.

What is the historical origin of Merck & Co., Inc.?

Merck & Co., Inc. originated from the Merck Group, which was founded in Germany in 1668. The American arm, now an independent company, was established to serve the United States and Canada.

Stock MRK logo
Merck & Co., Inc.

NYSE:MRK

MRK Rankings

#34 Ranked by Market Cap
#933 Ranked by Dividends

MRK Stock Data

256.11B
2.53B
0.06%
79.47%
1.04%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
KENILWORTH